A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 7211-7221

  Belyakov, Igor M ^a   Isakov, Dmitry ^a   Zhu, Qing ^a   Dzutsev, Amiran ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOREACTIVITY; INFECTION RESISTANCE; INTERFERON PRODUCTION; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECTUM MUCOSA; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN CELL; T CELL DEPLETION; TISSUE DISTRIBUTION;

EID: 34249786561     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.7211     Document Type: Article

References (75)

1. Bienenstock, J., A. D. Befus, M. McDermott, S. Mirski, K. Rosenthal, and A. Tagliabue. 1983. The mucosal immunological network: compartmentalization of lymphocytes, natural killer cells, and mast cells. Ann. NY Acad. Sci. 409: 164-170.
2. Brandtzaeg, P., I. N. Farstad, and G. Haraldsen. 1999. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today 20: 267-277.
3. Kemble, G., and H. Greenberg. 2003. Novel generations of influenza vaccines. Vaccine 21: 1789-1795.
4. + T cell immunity in the lung by CpG ODN increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J. Immunol. 177: 6336-6343.
5. Czerkinsky, C., and J. Holmgren. 1994. Exploration of mucosal immunity in humans: relevance to vaccine development. Cell. Mol. Biol. 40(Suppl. 1): 37-44.
6. Koprowski, H. 2006. First decade (1950-1960) of studies and trials with the polio vaccine. Biologicals 34: 81-86.
7. Belyakov, I. M., Z. Hel, B. Kelsall, V. A. Kuznetsov, J. D. Ahlers, J. Nacsa, D. Watkins, T. M. Allen, A. Sette, J. Altman, et al. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7: 1320-1326.
8. + CTLs in delay of AIDS-viral dissemination from mucosa. Blood 107: 3258-3264.
9. Baba, T. W., V. Liska, R. Hofmann-Lehmann, J. Vlasak, W. Xu, S. Ayehunie, L. A. Cavacini, M. R. Posner, H. Katinger, G. Stiegler, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6: 200-206.
10. McMichael, A. J. 2006. HIV vaccines. Annu. Rev. Immunol 24: 227-255.
11. + T cell depletion and viral replication in SIV infection. Science 280: 427-431.
12. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77: 11708-11717.
13. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200: 761-770.
14. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200: 749-759.
15. + T cells. Science 286: 1353-1357.
16. Miller, C. J., N. J. Alexander, S. Sutjipto, A. A. Lackner, A. Gettie, A. G. Hendrickx, L. J. Lowenstine, M. Jennings, and P. A. Marx. 1989. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63: 4277-4284.
17. + T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J. Virol. 81: 599-612.
18. Mehandru, S., M. A. Poles, K. Tenner-Racz, P. Jean-Pierre, V. Manuelli, P. Lopez, A. Shet, A. Low, H. Mohri, D. Boden, et al. 2006. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3: e484.
19. + T cells. Nature 434: 1148-1152.
20. + T cells in lymphoid tissues during simian immunodeficiency virus infection. J. Virol. 74: 11001-11007.
21. + T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
22. Harouse, J. M., A. Gettie, R. C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284: 816-819.
23. + T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. USA 101: 12324-12329.
24. Mattapallil, J. J., D. C. Douek, A. Buckler-White, D. Montefiori, N. L. Letvin, G. J. Nabel, and M. Roederer. 2006. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203: 1533-1541.
25. Neutra, M. R., and P. A. Kozlowski. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6: 148-158.
26. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1: 209-219.
27. Ahlers, J. D., I. M. Belyakov, and J. A. Berzofsky. 2003. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr. Mol. Med. 3: 285-301.
28. Hone, D. M., A. L. DeVico, T. R. Fouts, D. Y. Onyabe, S. M. Agwale, C. O. Wambebe, W. A. Blattner, R. C. Gallo, and G. K. Lewis. 2002. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments. J. Hum. Virol. 5: 17-23.
29. Belyakov, I. M., and J. A. Berzofsky. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247-253.
30. Belyakov, I. M., J. D. Ahlers, and J. A. Berzofsky. 2004. Mucosal AIDS vaccines: current status and future directions. Expert Rev. Vaccines 3(Suppl.): 65-73.
31. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57: 183-289.
32. Berzofsky, J. A., J. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and I. M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 114: 450-462.
33. Staats, H. F., S. P. Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13: 945-952.
34. Lehner, T., L. Bergmeier, Y. Wang, L. Tao, and E. Mitchell. 1999. A rational basis for mucosal vaccination against HIV infection. Immunol. Rev. 170: 183-196.
35. Mestecky, J., and P. N. Fultz. 1999. Mucosal immune system of the human genital tract. J. Infect. Dis. 179(Suppl. 3): S470-S474.
36. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164: 1602-1611.
37. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95: 1709-1714.
38. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102: 2072-2081.
39. Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol. Rev. 170: 151-172.
40. + T-cell responses in mucosal tissues of macaques. J. Virol. 76: 11659-11676.
41. + T-cell loss and reduces both systemic and mucosal SHIVKU2 RNA levels. J. Virol. 80: 3732-3742.
42. Vogel, T. U., M. R. Reynolds, D. H. Fuller, K. Vielhuber, T. Shipley, J. T. Fuller, K. J. Kunstman, G. Sutter, M. L. Marthas, V. Erfle, et al. 2003. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIV-mac239. J. Virol. 11: 13348-13360.
43. Horner, A. A., S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N. Cinman, M.-D. Nguyen, J. H. Van Uden, J. A. Berzofsky, D. D. Richman, and E. Raz. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167: 1584-1591.
44. KU2-infected macaques. J. Virol. 75: 11483-11495.
45. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, and D. I. Watkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50: 657-661.
46. Berzofsky, J. A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88: 876-884.
47. Ahlers, J. D., I. M. Belyakov, E. K. Thomas, and J. A. Berzofsky. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108: 1677-1685.
48. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13: 897-908.
49. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187: 1373-1381.
50. + lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J. Virol. 75: 738-749.
51. + T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201: 95-104.
52. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100: 9458-9463.
53. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96: 4512-4517.
54. Belyakov, I. M., S. A. Hammond, J. D. Ahlers, G. M. Glenn, and J. A. Berzofsky. 2004. Transcutaneous immunization induces mucosal CTL and protective immu-nity by migration of primed skin dendritic cells. J. Clin. Invest. 113: 998-1007.
55. Lefrancois, L. 1987. Carbohydrate differentiation antigens of murine T cells: expression on intestinal lymphocytes and intestinal epithelium. J. Immunol. 138: 3375-3384.
56. Belyakov, I. M., J. Wang, R. Koka, J. D. Ahlers, J. T. Snyder, R. Tse, J. Cox, J. S. Gibbs, D. H. Margulies, and J. A. Berzofsky. 2001. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. Eur. J. Immunol. 31: 3557-3566.
57. Kuznetsov, V. A., V. S. Stepanov, J. A. Berzofsky, and I. M. Belyakov. 2004. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. J. Clin. Virol. 31(Suppl. 1): S69-S82.
58. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J. Virol 72: 8264-8272.
59. Gallichan, W. S., and K. L. Rosenthal. 1996. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184: 1879-1890.
60. + T cell population in different tissues. Vaccine 22: 1390-1394.
61. + T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 74: 8762-8766.
62. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
63. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H. G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187: 1647-1657.
64. Snyder, J. T., M. A. Alexander-Miller, J. A. Berzofsky, and I. M. Belyakov. 2003. Molecular mechanisms and biological significance of CTL avidity. Curr. HIV Res. 1: 287-294.
65. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63: 1617-1623.
66. McKay, P. F., J. E. Schmitz, D. H. Barouch, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, D. A. Gorgone, and N. L. Letvin, 2002. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 168: 332-337.
67. + T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192: 63-75.
68. + T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 176: 5338-5345.
69. + T cells following early HIV-1 infection. J. Virol. 81: 4199-4214.
70. + T cells with regime-dependent cytokine/granzyme B profiles. J. Immunol. 178: 2370-2379.
71. Oh, S., J. W. Hodge, J. D. Ahlers, D. S. Burke, J. Schlom, and J. A. Berzofsky. 2003. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J. Immunol. 170: 2523-2530.
72. + T cells. Proc. Natl. Acad. Sci. USA 101: 15154-15159.
73. Belyakov, I. M., J. D. Ahlers, J. D. Clements, W. Strober, and J. A. Berzofsky. 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165: 6454-6462.
74. Porgador, A., H. F. Staats, B. Faiola, E. Gilboa, and T. J. Palker. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158: 834-841.
75. Staats, H. F., C. P. Bradney, W. M. Gwinn, S. S. Jackson, G. D. Sempowski, H. X. Liao, N. L. Letvin, and B. F. Haynes. 2001. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 167: 5386-5394.